--- title: "MBX Biosciences (NASDAQ:MBX) Sets New 12-Month High - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/293773254.md" description: "MBX Biosciences (NASDAQ:MBX) reached a new 52-week high of $66.66, closing at $61.10. Analysts recently adjusted ratings and price targets; Truist raised its target to $70 with a 'buy' rating, while Citizens Jmp increased its target to $86. The consensus rating is 'Moderate Buy' with an average target of $66.75. Additionally, several institutional investors, including Stempoint Capital and California State Teachers Retirement System, significantly increased their stakes in the first quarter." datetime: "2026-07-24T15:00:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293773254.md) - [en](https://longbridge.com/en/news/293773254.md) - [zh-HK](https://longbridge.com/zh-HK/news/293773254.md) --- # MBX Biosciences (NASDAQ:MBX) Sets New 12-Month High - Here's Why MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $66.66 and last traded at $61.10, with a volume of 107404 shares changing hands. The stock had previously closed at $63.57. Get **MBX Biosciences** alerts: ## Analyst Ratings Changes Several research analysts have recently commented on the company. Truist Financial raised their price target on MBX Biosciences from $50.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Citigroup reiterated an "outperform" rating on shares of MBX Biosciences in a report on Tuesday, May 12th. Citizens Jmp increased their target price on MBX Biosciences from $76.00 to $86.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 12th. Stifel Nicolaus set a $56.00 target price on MBX Biosciences in a research report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, MBX Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $66.75. **View Our Latest Stock Analysis on MBX Biosciences** ## MBX Biosciences Trading Down 3.1% The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -27.81 and a beta of 0.16. The stock's fifty day simple moving average is $44.81 and its 200-day simple moving average is $37.72. ## Institutional Investors Weigh In On MBX Biosciences Several large investors have recently bought and sold shares of the stock. Stempoint Capital LP raised its position in MBX Biosciences by 535.8% in the 1st quarter. Stempoint Capital LP now owns 499,469 shares of the company's stock valued at $14,909,000 after purchasing an additional 420,916 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in MBX Biosciences in the first quarter valued at approximately $308,000. California State Teachers Retirement System lifted its stake in MBX Biosciences by 1,197.9% in the first quarter. California State Teachers Retirement System now owns 22,765 shares of the company's stock worth $680,000 after acquiring an additional 21,011 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in MBX Biosciences by 1.9% in the first quarter. Rock Springs Capital Management LP now owns 287,967 shares of the company's stock worth $8,596,000 after acquiring an additional 5,343 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in MBX Biosciences by 30.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 90,634 shares of the company's stock worth $2,705,000 after acquiring an additional 21,083 shares in the last quarter. ## MBX Biosciences Company Profile (Get Free Report) We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. ## Recommended Stories - Five stocks we like better than MBX Biosciences - CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test - Plugging In: How Kinder Morgan Powers Up Profits - Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough - TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in MBX Biosciences Right Now? Before you consider MBX Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list. While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MBX.US](https://longbridge.com/en/quote/MBX.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [CFG.US](https://longbridge.com/en/quote/CFG.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [JHG.US](https://longbridge.com/en/quote/JHG.US.md) - [MFC.US](https://longbridge.com/en/quote/MFC.US.md) - [KMI.US](https://longbridge.com/en/quote/KMI.US.md) - [FCX.US](https://longbridge.com/en/quote/FCX.US.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [CRWD.US](https://longbridge.com/en/quote/CRWD.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md) - [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md) - [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) ## Related News & Research - [MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/294163609.md) - [MBX Biosciences (MBX) Leadership Shake-Up: How Might New Management Reframe Its Investment Narrative?](https://longbridge.com/en/news/293479094.md) - [Scorpio Gold pursues Nasdaq listing for American depositary shares](https://longbridge.com/en/news/293905134.md) - [Scorpio Gold Moves to Launch Nasdaq ADS Listing to Expand U.S. Investor Reach](https://longbridge.com/en/news/293950190.md) - [Precision BioSciences (DTIL) Expected to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294326691.md)